Challenges in Diagnosis, Surveillance and Prevention of Ventilator-associated pneumonia

Massachusetts Coalition for the Prevention of Errors November 6, 2008

Michael Klompas MD, MPH, FRCPC

Brigham and Women's Hospital Harvard Medical School



Outline

- 1. Why is there a movement to report VAP?
- 2. How accurate is clinical diagnosis of VAP?
- 3. What are the implications for VAP surveillance and reporting?
- 4. BWH approach to surveillance
- 5. What can we do to prevent VAP?



Why is there a push to report VAP?




Ventilator-associated pneumonia

- Most common nosocomial infection in ICU's
- Affects ~10% of ventilated patients
- Increases ICU length of stay by ~5 days
- Crude mortality rate of 30-50%
- VAP patients about 2x as likely to die as matched patients without VAP
- Adds ~\$10-15,000 to cost of hospital stay



Institute for Healthcare Improvement




- Rapid Response Teams
- Evidence-based care for MI
- Prevent adverse drug events
- Prevent central line infections
- Prevent ventilator-associated pneumonia



Mandatory Reporting Legislation

Mandatory reporting enacted Study bill








Nonpayment for Performance? Medicare's New Reimbursement Rule

Meredith B. Rosenthal, Ph.D.

"Recently, the Centers for Medicare and Medicaid Services (CMS) announced its decision to cease paying hospitals for some of the care made necessary by 'preventable complications'"



These initiatives all presume we can accurately identify and track healthcare-associated infections


...but ventilator-associated pneumonia (VAP) is a difficult diagnosis



The Challenge of VAP Diagnosis

- Many complications of critical care present with clinical signs that can mimic VAP
 - Radiographic opacities
 - ✓ Fever
 - ✓ Abnormal white blood cell count
 - Impaired oxygenation
 - Increased pulmonary secretions







"Diffuse patchy airspace disease left greater than right with obliteration of both hemi-diaphragms. Opacities possibly slightly increased since yesterday accounting for changes in patient position and inspiration. This could represent atelectasis, pneumonia, or effusion."



Fever and pulmonary densities

- Prospective study of 50 patients clinically suspected of having VAP on the basis of fever and pulmonary densities. On intensive investigation:
 - ✓ Only 42% confirmed to have VAP
 - Most patients had 2 or more diagnoses



Pulmonary Densities

- Pneumonia
- ARDS
- Congestive heart failure
- Atelectais
- Pulmonary infarction

Fever

- Pneumonia
- Sinusitis
- Bloodstream infection
- Urinary tract infection
- Gall bladder disease
- Empyema
- Peritonitis
- ARDS (lung inflammation)
- Chemical aspiration
- Pancreatitis
- Drug fever



Physician diagnosis poor

- Series of 84 ICU patients with abnormal chest xrays and purulent sputum
 - Evaluated by 7 physicians for VAP
 - ✓ "True diagnosis" established by histology or quantitative bronchoscopy cultures
 - ✓ 32% found to have VAP



Physician agreement and accuracy poor

- Physicians disagreed on presence or absence of VAP in 35/84 (42%) of patients
 - ✓ The "best" doc missed 28% of true VAP's
 - ✓ The "worst" doc missed 50% of true VAP's
 - ✓ Both labeled ~20% of patients without VAP as having VAP



Infection control practitioner agreement poor

 90 sick patients from Brigham ICU's evaluated for VAP by two infection control practitioners

Practioner 2

		VAP present	VAP absent
Practioner 1	VAP present	15	4
Practi	VAP absent	17	54



disagreement on 21/90 (23%) of patients!

Are there any clinical signs that reliably indicate VAP?




Evaluation of clinical signs to diagnose VAP

- Systematic search of Medline and Google Scholar to find every English-language study ever published evaluating the accuracy of clinical, radiographic, and laboratory data to diagnose VAP relative to lung biopsy as gold standard
 - √ 14 studies describing 655 patients



Accuracy of Clinical Signs for VAP






- 95% confidence interval

Klompas, JAMA 2007; 297:1583

Accuracy of Bacterial Cultures for VAP






—— 95% confidence interval

Klompas, JAMA 2007; 297:1583

Accuracy of Findings in Combination for VAP





——— 95% confidence interval

Klompas, JAMA 2007; 297:1583

What are the implications of diagnostic uncertainty for VAP surveillance?



CDC Surveillance Definition of VAP

Patient must fulfill each of the three categories below:

Chest Radiograph	Any one of the following: 1. New, progressive, or persistent infiltrate 2. Consolidation 3. Cavitation
Systemic Signs	 Any one of the following: Temperature >38°C WBC <4,000 or >12,000 WBC/mm³ For adults 70 years old, altered mental status with no other recognized cause
Pulmonary Signs	 Any two of the following: New onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements New onset or worsening cough, or dyspnea, or tachypnea Rales or bronchial breath sounds Worsening gas exchange, increased oxygen requirements, or increased ventilation demand



Problems with CDC VAP Criteria

- Subjective
 - "change in character of sputum"
 - "worsening gas exchange"
- Non-specific
 - "rales"
 - "delirium"
 - "new or progressive infiltrate"
- Labour intensive to gather
 - "increased suctioning requirements"
 - "new onset tachypnea"
- Liable to be gamed if hospitals' reputations and compensation become linked to VAP rates



Where does this leave hospitals?

We need to publicly report VAP rates to catalyze improved quality of care and save lives!

But the definition of VAP is ambiguous, hard to implement, and open to be gamed!









BWH Approach to VAP Surveillance

- Refine the CDC surveillance definition
 - Reduce ambiguity
 - ✓ Improve reproducibility
 - Enable electronic collection of all variables
 - Retain validity by remaining faithful to the structure and content of the CDC definition



BWH Modified CDC Criteria

Chest Radiograph	 Any one of the following: 1. Opacity, infiltrate, or consolidation that appears, evolves, or persists over ≥72 hours 2. Cavitation
Systemic Signs	 Any one of the following: 1. Temperature >100.4°F within past 24 hours 2. WBC <4,000 or >12,000 WBC/mm³ within past 24 hours
Pulmonary Signs	 Both of the following 1. Sustained rise in ventilator FiO2 ≥ 15mm Hg OR rise in PEEP by ≥2.5cm H₂O sustained for ≥ 48 hours 2. Gram stain of respiratory secretions with moderate (2+) or more neutrophils per high power field within past 72 hours






VAP Screening – An Approach

- Use the "change in oxygenation" criteria as a screen – if a patient's ventilator settings are stable then they do not have VAP
- Only review temperature, white blood cell count, sputum gram stain, and xray if ventilator-change criteria are met





$Ventilator\ Management-VAP\ Surveillance$


Ventilator Day


<i>MR</i> N	Patient Name	Unit	Room	Intubation Date	Current Intub. Day	Total Days Since 1st Intubated	Date	PEEP	FIO2	Daily Max Temp
		7C	52	10/25/2006						
					1	1	10/25/2006	5	60	
					2	2	10/26/2006	5	40	95.2
					3	3	10/27/2006	5	40	98.7
					4	4	10/28/2006	5	40	101.2
					5	5	10/29/2006	5	40	101.3
					6	6	10/30/2006	5	40	101.8


Total Patient-Ventilator Days


Page: IK ⊀

1 ▶ Ы ◀









Validation

- Blinded retrospective comparison of electronic surveillance versus CDC criteria in 197 patients ventilated >48 hours in MICU or SICU
 - ✓ Sample enriched with patients ventilated ≥ 7 days
 - CDC criteria determined by consensus of independent reviews by 2 infection control practitioners



Time to Complete VAP Surveillance for 200 Patients Ventilated >48 Hours

	Total Time	Average Time per Chart	
Nurse Reviewer	170 hours	~45 mins	
Electronic Algorithm	7 hours	~2 mins	



VAP Surveillance Algorithm versus CDC ICP Consensus

	CDC Positive	CDC Negative
Algorithm Positive	10	19
Algorithm Negative	5	163

Sensitivity 67% Specificity 90% PPV 35% NPV 97%



Interobserver Agreement (preliminary results)

	Kappa
Agreement between ICP 1 and ICP 2	0.44
Agreement between ICP consensus and algorithm	0.39




Who is right? High interobserver variability No clear way of knowing "truth"

We need to start looking at outcomes rather than events




Electronic versus NHSN Surveillance as predictors of patient outcomes





Electronic versus NHSN Surveillance as predictors of patient outcomes





How about the process measures?



VAP Prevention Measures

	Impact on
	VAP Rates
Daily interruption of sedation	↓ 64%
Daily assessment of readiness to extubate	↓ 10%
Head-of-bed elevation	↓ 78%
Regular oral care with chlorhexidine	↓ 40-60%



NEJM 2000;342:1471 Crit Care Med 2004;32:1272

Chest 2000;118:459

Am J Respir Crit Care Med 2006;174:894

Lancet 1999;354:1851

BMJ 2007;334:889

VAP Prevention Measures

	Vent LOS	ICU LOS	Hospital LOS	Mortality
Sedative interruption			X	X
Readiness to extubate			X	X
Head-of-bed elevation	X	X	X	X
Regular oral care	X	X	X	X



VAP Prevention Measures

	Vent LOS	ICU LOS	Hospital LOS	Mortality
Sedative interruption AND Readiness to extubate				

Is this a hint that bundles might improve outcomes beyond each measure alone?



No reliable studies yet but...

- Multiple reports of dramatic decreases in VAP rates following implementation of VAP bundle
- No control groups! INTERPRET WITH GREAT CAUTION

	Vent LOS	ICU LOS	Hospital LOS	Mortality
Mayo Clinic, Jacksonville, FL				
East Surrey Hospital, UK				X
University of Kansas				X



Mayo Clin Proc 1996;81:849 Nursing Crit Care 2005;10:242 Surgical Infections 2007;8:505

VAP - The Bottom Line

- VAP is unreliable for measuring quality of care or for benchmarking hospitals
- A quantitative adaption of the CDC VAP definition is promising but needs further validation
- We need to develop new measures to assess quality of care for ventilated patients
 - ✓ Objective, easy to gather (electronic), predict outcomes
- Process measures are a reasonable interim step until better outcome measures can be developed
 - Daily sedation vacation
 - ✓ Daily assessment of readiness to wean
 - Bundles promising



Manual application of the BWH Surveillance Protocol

- Place a surveillance data sheet at the bedside of each patient
- RT, RN, MD, and/or ICP fills in small amount of data daily
- ICP collect sheets once a week or once a month to review

Date	PEEP	FiO2	Temp	WBC	Sputum	Gram	CXR
					or	stain	opacity
					Bronch	polys	
Nov 1	10	100	99.2	12.1	No		No
Nov 2	5	60	99.1	8.2	No		No
Nov 3	5	40	100.0	7.7	No		No
Nov 4	5	40	98.6	7.4	Yes	1+	No
Nov 5	5	40	97.7	5.6	No		No
Nov 6							



Thank you

- Richard Platt
- Deborah Yokoe
- Martin Kulldorff
- Ken Kleinman
- Susan Huang
- Susan Marino

- Elise Tamplin
- Maggie Bikowski
- Tricia Lemon
- Paul Nuccio
- Rose Villarreal
- Pam Fox

Enquiries Welcome!

Michael Klompas mklompas@partners.org

